-

KSQ Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced that the company is scheduled to present at the Oppenheimer 31st Annual Healthcare Conference, to be held virtually, on Tuesday, March 16th, 2021, at 4:30 p.m. ET.

About KSQ Therapeutics

KSQ Therapeutics is advancing a pipeline of tumor- and immune-focused drug candidates for the treatment of cancer across multiple drug modalities including targeted therapies, adoptive cell therapies and immuno-therapies. KSQ’s proprietary CRISPRomics® discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies. For more information, please visit the company’s website at www.ksqtx.com and follow @ksq_tx on Twitter.

Contacts

Cory Tromblee
Tel: 617-571-7220
cory@scientpr.com

Industry:

KSQ Therapeutics

Release Versions
English

Contacts

Cory Tromblee
Tel: 617-571-7220
cory@scientpr.com

More News From KSQ Therapeutics

KSQ Therapeutics and CTMC Announce Strategic Collaboration to Accelerate the Development of Novel Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapies for the Treatment of Solid Tumors

LEXINGTON, Mass.--(BUSINESS WIRE)--KSQ Therapeutics, Inc. ("KSQ"), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, and CTMC, a joint venture between National Resilience, Inc. and MD Anderson Cancer Center, announced today a strategic collaboration to expedite the development of KSQ's two lead engineered tumor-infiltrating lymphocyte (eTIL®) programs, KSQ-001EX and KSQ-004EX, both of which are advancing toward clinical stu...

KSQ Therapeutics Enters Worldwide License Agreement with Roche for KSQ-4279, a Clinical-Stage USP1 Inhibitor for Cancer

LEXINGTON, Mass.--(BUSINESS WIRE)--KSQ Therapeutics, Inc. (“KSQ”), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, announced today it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279. KSQ-4279 is a first-in-class, potent, and selective small molecule inhibitor of USP1, a protein that regulates DNA damage response (DDR) in a manner distinct fr...

KSQ Therapeutics and Takeda Expand Strategic Immuno-Oncology Collaboration to Identify and Validate Novel Tumor Targets

LEXINGTON, Mass.--(BUSINESS WIRE)--KSQ Therapeutics, (“KSQ”), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, announced today that it has expanded its strategic collaboration with Takeda to research and validate novel tumor-intrinsic targets. Under the terms of the agreement, Takeda will provide KSQ with an upfront payment and an investment in the double-digit millions of dollars. KSQ is also eligible to receive up to $51...
Back to Newsroom